


Rosiglitazone

#Cat: NB-64-00499-1mL	Size: 1 mL
#Cat: NB-64-00499-25mg	Size: 25 mg
#Cat: NB-64-00499-50mg	Size: 50 mg
#Cat: NB-64-00499-100mg	Size: 100 mg
#Cat: NB-64-00499-200mg	Size: 200 mg
#Cat: NB-64-00499-500ug	Size: 500 mg

Chemical Properties:

CAS No:	122320-73-4
Formula:	C ₁₈ H ₁₉ N ₃ O ₃ S
Molecular Weight:	357.43
Appearance:	Solid
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description:

Description	Rosiglitazone (BRL49653) is a PPAR γ agonist, TRPC5 activator, and TRPM3 inhibitor with oral activity. Rosiglitazone is also a hypoglycemic agent and a thiazolidinedione insulin sensitizer.
Targets (IC50)	Apoptosis, Ferroptosis, Autophagy, PPAR, TRP/TRPV Channel
In vitro	Rosiglitazone reduces bone formation rate and increases adipose content within the bone marrow. It decreases the expression of osteoblast-specific genes Runx2/Cbfa1, DLX5, and α 1(I) collagen, while expression of the adipocyte-specific fatty acid binding protein AP2 is increased. This drug leads to significant bone loss, evidenced by reductions in bone mass, trabecular width, and number, along with an increase in trabecular separation. Furthermore, in ob/ob mice, rosiglitazone enhances transcription of genes encoding mitochondrial proteins in white adipocytes, which is accompanied by changes in mitochondrial number and structure.
In vivo	In certain cell lines, Rosiglitazone reduces cholesterol synthesis independent of peroxisome proliferator-activated receptor γ (PPAR γ). The compound significantly enhances the phosphorylation of threonine 172 in the α subunit of AMP-dependent protein kinase, increasing the AMP: ATP ratio. Additionally, Rosiglitazone boosts secretion of adiponectin by up to 2.3-fold from omental cells, while secretion from subcutaneous fat cells remains unaffected. In 3T3-L1 adipocytes, Rosiglitazone alters mitochondrial morphological characteristics and protein profile. It activates complexes containing α 1- and α 2-AMPK, leading to a marked increase in phosphorylation of acetyl-CoA carboxylase. Rosiglitazone also acts as a dominant inhibitor of osteoblastogenesis from mouse marrow in vitro through the activation of PPAR γ 2.
Cell Research	Rosiglitazone is dissolved in DMSO and stored, and then diluted with appropriate medium before use[2]. Human neuroblastoma SH-SY5Y cells are maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 μ g/mL Streptomycin and 100 U/mL Penicillin G. SH-SY5Y cells are transfected with the longest isoform of human tau (2N4R) tagged with GFP using lipofectamine. 24 hr after transfection, cells are treated with Rosiglitazone (10 μ M, 50 μ M) for 24 hr[2].

Solubility Information

Solubility	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.58 mg/mL (10.02 mM), Suspension. DMSO: 262.5 mg/mL (734.41 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
-------------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.7978 mL	13.9888 mL	27.9775 mL
5 mM	0.5596 mL	2.7978 mL	5.5955 mL
10 mM	0.2798 mL	1.3989 mL	2.7978 mL
50 mM	0.056 mL	0.2798 mL	0.5596 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

- Cellai I, et al. Antineoplastic effects of rosiglitazone and PPAR γ transactivation in neuroblastoma cells. *Br J Cancer*. 2006 Oct 9;95(7):879-88.
- Zeng X, Zhu S, Lu W, et al. Target identification among known drugs by deep learning from heterogeneous networks. *Chemical Science*. 2020, 11(7): 1775-1797.
- Li Y, Rui G, Yang Z, et al. Liraglutide modulates lipid metabolism via ZBTB20-LPL pathway. *Life Sciences*. 2024: 123267.
- Miao Y, Wu X, Xue X, et al. Morin, the PPAR γ agonist, inhibits Th17 differentiation by limiting fatty acid synthesis in collagen-induced arthritis. *Cell Biology and Toxicology*. 2022: 1-20.
- Lin CF, et al. Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN. *Biomed Res Int*. 2014; 2014:787924.
- García-Ruiz I, et al. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. *Hepatology*. 2007 Aug;46(2):414-23.
- Qiu Y, Sun Y, Xu D, et al. Screening of FDA-approved drugs identifies sutent as a modulator of UCP1 expression in brown adipose tissue. *EBioMedicine*. 2018, 37: 344-355.
- Miao Y, Geng Y, Yang L, et al. Morin inhibits the transformation of fibroblasts towards myofibroblasts through regulating "PPAR- γ -glutaminolysis-DEPTOR" pathway in pulmonary fibrosis. *The Journal of Nutritional Biochemistry*. 2021: 108923.
- Wiggin TD, et al. Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin-treated DBA/2J mice. *Endocrinology*. 2008 Oct;149(10):4928-37.
- Miao Y, Zhang C, Yang L, et al. The activation of PPAR γ enhances Treg responses through up-regulating CD36/CPT1-mediated fatty acid oxidation and subsequent N-glycan branching of T β R11/IL-2R α . *Cell Communication and Signaling*. 2022, 20(1): 1-22
- Li J, Bai Y, Liu Y, et al. Transcriptome-based chemical screens identify CDK8 as a common barrier in multiple cell reprogramming systems. *Cell Reports*. 2023, 42(6).
- Ateyya H, et al. Beneficial effects of rosiglitazone and losartan combination in diabetic rats. *Can J Physiol Pharmacol*. 2018 Mar;96(3):215-220.
- Qiu Y, Sun Y, Xu D, et al. Screening of FDA-approved drugs identifies sutent as a modulator of UCP1 expression in brown adipose tissue[J]. *EBioMedicine*. 2018, 37: 344-355.
- Chen S, Zhou X, Li W, et al. Development of a novel peptide targeting GPR81 to suppress adipocyte-mediated tumor progression. *Biochemical Pharmacology*. 2023: 115800.
- Zeng X, Zhu S, Lu W, et al. Target identification among known drugs by deep learning from heterogeneous networks[J]. *Chemical Science*. 2020, 11(7): 1775-1797.
- Schöckel L, Woischke C, Surendran S A, et al. PPAR γ activation promotes the proliferation of colorectal cancer cell lines and enhances the antiproliferative effect of 5-fluorouracil. *BMC cancer*. 2024, 24(1): 1-12.
- Huang Q, Ru Y, Luo Y, et al. Identification of a targeted ACSL4 inhibitor to treat ferroptosis-related diseases. *Science Advances*. 2024, 10(13): eadk1200.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use